Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.44 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.44 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11824862 | 1.00 | CYP17A1 (0.48) | CYP17A1CYP19A1LMNAKMT2ATDP1 | |
| Hydrochloric Acid SCHEMBL11824849 | 0.99 | CYP17A1 (0.47) | CYP17A1CYP19A1LMNAKMT2ATDP1 | |
| Hydrochloric Acid SCHEMBL11824857 | 0.99 | CYP17A1 (0.47) | CYP17A1CYP19A1LMNAKMT2ATDP1 | |
| SCHEMBL11825984 | 0.88 | KMT2A (0.50) | CYP17A1CYP19A1LMNAKMT2ATDP1 | |
| Hydrochloric Acid SCHEMBL11825978 | 0.87 | KMT2A (0.49) | CYP17A1CYP19A1LMNAKMT2ATDP1 | |
| Hydrochloric Acid SCHEMBL11825975 | 0.87 | KMT2A (0.49) | CYP17A1CYP19A1LMNAKMT2ATDP1 | |
| SCHEMBL8861398 | 0.85 | KMT2A (0.51) | CYP17A1CYP19A1LMNAKMT2ATDP1 | |
| SCHEMBL22752185 | 0.84 | KMT2A (0.53) | CYP17A1CYP19A1LMNAKMT2ATDP1 | |
| SCHEMBL11831400 | 0.83 | CYP17A1 (0.46) | CYP17A1CYP19A1LMNAKMT2ATDP1 | |
| Hydrochloric Acid SCHEMBL11831393 | 0.82 | CYP17A1 (0.45) | CYP17A1CYP19A1LMNAKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304603-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, LLC | 2023-04-27 | — | — | US | disclosed |
| US-11578087-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| EP-3578562-B1 | L-VALINATE AMIDE BENZOXABOROLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | ANACOR PHARMACEUTICALS INC (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. | 2021-04-08 | — | — | US | disclosed |
| US-10882872-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10562921-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3578562-A1 | L-VALINATE AMIDE BENZOXABOROLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | Anacor Pharmaceuticals, Inc (US) | 2019-12-11 | — | — | EP | disclosed |
| CN-109503637-A | For treating the noval chemical compound of the disease of helminth | 安纳考尔医药公司 | 2019-03-22 | — | — | CN | disclosed |
| EP-3455227-A1 | OXABOROLE ESTERS AND USES THEREOF | Anacor Pharmaceuticals, Inc (US) | 2019-03-20 | — | — | EP | disclosed |
| CN-109153688-A | Oxaborolidine esters and uses thereof | 安纳考尔医药公司 | 2019-01-04 | — | — | CN | disclosed |
| US-20170327519-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| WO-2017195069-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304603-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | CYP17A1 689/4885CYP19A1 699/4885LMNA 2067/4885 |
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | CYP17A1 689/4885CYP19A1 699/4885LMNA 2067/4885 |
| US-10882872-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | CYP17A1 689/4885CYP19A1 699/4885LMNA 2067/4885 |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | CYP17A1 689/4885CYP19A1 699/4885LMNA 2067/4885 |
| US-11578087-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | CYP17A1 689/4885CYP19A1 699/4885LMNA 2067/4885 |
| US-20170327519-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | CYP17A1 689/4885CYP19A1 699/4885LMNA 2067/4885 |
| US-10562921-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | CYP17A1 689/4885CYP19A1 699/4885LMNA 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.